Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 13:00 source : Investors.biomarin.com save search
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA
Published: 2024-01-03 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: 0.96%
H: 0.0%
C: -2.33%
conference
BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
Published: 2023-09-06 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -0.43%
H: 1.25%
C: 0.72%
day pipeline
BioMarin to Host First Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, April 26, at 4:30pm ET
Published: 2023-04-13 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -0.66%
H: 1.71%
C: 1.06%
conference financial results
BioMarin to Host Fourth Quarter and Full-Year 2022 Financial Results Conference Call and Webcast on Monday, February 27, at 4:30 p.m. ET
Published: 2023-02-07 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -0.64%
conference financial results
BioMarin to Participate in Two Upcoming Investor Conferences
Published: 2022-11-03 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: 0.5%
H: 1.19%
C: 0.34%
BioMarin to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, October 26, at 4:30pm ET
Published: 2022-10-04 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: 0.55%
H: 1.03%
C: 0.84%
conference financial results
BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report
Published: 2022-09-15 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -0.26%
H: 1.82%
C: 1.69%
report therapy
BioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress July 9-12, Including 4 Oral and 2 Poster Presentations
Published: 2022-07-11 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: 1.6%
H: 0.12%
C: -1.24%
international
BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
Published: 2022-05-31 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: 1.91%
H: 0.01%
C: -6.6%
ongoing therapy phase 1
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations
Published: 2022-05-05 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: 1.13%
H: 0.19%
C: -2.58%
ongoing platform
BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amET
Published: 2022-05-04 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: 0.07%
H: 0.0%
C: 0.0%
BioMarin to Host First Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, April 27, at 4:30pm ET
Published: 2022-04-13 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -0.15%
H: 2.32%
C: 1.86%
conference results
BioMarin to Participate in Four Upcoming Virtual Investor Conferences
Published: 2021-10-25 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -1.34%
H: 0.48%
C: -0.39%
conference
BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations
Published: 2021-10-04 (Crawled : 13:00) - investors.biomarin.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: 2.38%
H: 0.75%
C: -8.18%
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -1.52%
H: 1.36%
C: -0.16%
BioMarin to Participate in Three Upcoming Virtual Investor Conferences
Published: 2021-08-25 (Crawled : 13:00) - investors.biomarin.com
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: 0.17%
H: 1.65%
C: 0.79%
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -0.23%
H: 2.08%
C: 1.89%
conference
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Published: 2021-07-15 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -0.36%
H: 0.76%
C: 0.23%
europe authorized application
BioMarin to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, July 28 at 4:30pm ET
Published: 2021-07-14 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: 0.2%
H: 0.14%
C: -2.42%
financial results results conference
BioMarin Announces 12 Presentations at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress
Published: 2021-07-02 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: 0.38%
H: 1.79%
C: 1.47%
presentation
BioMarin Resubmits Marketing Authorization Application (MAA) to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Published: 2021-06-28 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: 1.18%
H: 0.63%
C: -1.59%
europe authorized application
BioMarin to Participate in the Virtual BofA Securities 2021 Napa Biopharma Conference
Published: 2021-06-15 (Crawled : 13:00) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -0.1%
H: 0.44%
C: -0.53%
biopharma conference
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.